Walgreens reported a fiscal first-quarter earnings and revenue that exceeded Wall Street’s expectations. The company’s shares soared 15% following the announcement. Despite a net loss of $265 million, or 31 cents per share, adjusted earnings were 51 cents per share. Sales for the quarter reached $39.46 billion, a 7.5% increase from the previous year. The U.S. retail pharmacy segment alone generated $30.87 billion, up 6.6%, with pharmacy sales rising 10.4% and comparable pharmacy sales increasing by 12.7%. Total prescriptions filled, including vaccines, were 316.3 million, up 1.5%. However, retail sales dropped by 6.2%, and comparable retail sales fell 4.6%. The U.S. health-care unit saw sales of $2.17 billion, a 12% increase, while the international segment, including Boots, reported $6.43 billion in sales, up 10.2%. Walgreens maintained its fiscal 2025 earnings guidance at $1.40 to $1.80 per share.
Source: www.cnbc.com
